---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022710"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2026-05-13T20:05:25+00:00"
generated_at: "2026-05-13T22:10:29.831361+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics Q1 2026: cash $6.9M; R&D spend down to $0.4M; DTC skincare launch planned mid-2026

## Summary
- Cash and cash equivalents $6.9M as of Mar 31, 2026, down from $7.5M at Dec 31, 2025; net ATM proceeds of $2.0M.
- R&D expenses fell to $0.4M from $1.3M YoY, reflecting reduced clinical spending; SG&A rose to $1.5M from $1.1M.
- Announced Tome skincare brand for DTC; first product (Foundational Treatment) expected to launch mid-2026.
- Hired Kyra Peckaitis as VP of Marketing to lead Tome brand; cash expected to fund operations into Q1 2027.

## SEC filing metadata
- accession: 0001493152-26-022710
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2026-05-13T20:05:25+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/0001493152-26-022710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022710
- JSON: https://secwatch.observer/filing/0001493152-26-022710.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022710.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.